Le Lézard
Classified in: Covid-19 virus

US Clinical Chemistry and Immunoassay In-Vitro Diagnostics Market, 2020: Demand for High-Volume Testing Driving the Growth of the Market - ResearchAndMarkets.com


The "Demand for High-Volume Testing Driving the Growth of the US Clinical Chemistry and Immunoassay In Vitro Diagnostics Market, 2020" report has been added to ResearchAndMarkets.com's offering.

The Transformational Health team provides critical insights into the US clinical chemistry and immunoassay industry, highlighting the recent activities, key growth opportunities, and trends that are shaping the industry.

The already dynamic in vitro diagnostics landscape in the United States was affected even more by the recent COVID-19 pandemic. Clinical laboratories and manufacturers have been vying to develop SARS-Cov-2 assays to serve the rising demand for testing. In these uncertain times, mergers, acquisitions, and partnerships have seen a considerable dip as compared with the previous year.

The US government and healthcare agencies are supporting telehealth and innovative and clinically vetted direct-to-consumer diagnostic testing services. Partnerships with digital vendors and automation companies are expected to empower core diagnostic companies with Internet of Things (IoT), cloud, and Big Data capabilities. Given these trends, it is important to understand the market dynamics to remain competitive and successful in the in vitro diagnostics market.

This report offers insightful analysis in the form of key growth opportunities that center on the use of serological testing, unmet testing needs for neuro-degenerative disorders, process flow improvement through IoT technologies, and the opportunity to include direct-to-consumer capabilities in business models.

Research Highlights

Key Topics Covered:

Strategic Imperatives

Growth Opportunities Fuel the Growth Pipeline Engine

Growth Opportunity Universe

For more information about this report visit https://www.researchandmarkets.com/r/g4j6dw


These press releases may also interest you

at 09:00
Coveo , a leading provider of enterprise AI Search, Recommendations and Generative Experience platforms that enable individualized, connected, and trusted digital experiences at scale with unified relevance, today announced two new GenAI business...

at 08:49
Cove Capital Investments reviews and analyzes nearly every type of asset class available for Delaware Statutory Trust investors.  This list of potential DST property asset classes includes government leased buildings, self-storage facilities,...

at 08:40
The "United States Self-Monitoring Blood Glucose Devices Market Growth, Share, Size, Trends, Analysis and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering. The U.S. Self-Monitoring Blood Glucose Devices market size...

at 08:35
Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX? digital platform. Participant Accident coverage is now available for child...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...



News published on and distributed by: